BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing / MedCity

Frank Vinluan / medcitynews - Infigratinib achieved statistically significant improvement in growth rate and body composition in a Phase 3 clinical trial that tested the BridgeBio Pharma drug in achondroplasia, the most common form of dwarfism. Regulatory submissions are planned for l…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda

---

Saturday, February 14, 2026, 12:22 am / permalink 19171 / 2 stories in 4 wks

Related Stories

---

• FDA lifts holds on Intellia’s Phase 3 gene-editing trials / 9 days
• FDA rejects Disc Medicine’s rare-disease drug despite priority review / 23 days
• Axpaxli outperforms Eylea in Phase 3; FDA filing expected / 27 days
• FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval / 5 wks
• FDA Accepts Summit Therapeutics' Ivonescimab BLA for EGFR‑Mutant NSCLC / 6 wks
• FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 6 wks
• FDA rejects Corcept’s cortisol modulator triggering setback / 2 months

Related Tags

---

StackHealth Time Machine

---